Labor Induction Clinical Trial
— TEAM LGAOfficial title:
Early Term Delivery Versus Expectant Management of the Large for Gestational Age Fetus (TEAM LGA Trial)
Verified date | December 2017 |
Source | The University of Texas Health Science Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare the incidence of composite neonatal morbidity and birthweight >4500 grams among uncomplicated large for gestational age (LGA) fetal growth at delivered 37 weeks versus expectant management.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 1, 2019 |
Est. primary completion date | July 1, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 39 Years |
Eligibility |
Inclusion Criteria: - Singleton pregnancy - Plan for vaginal delivery. Patients with prior cesarean section are eligible if they are planning for a trial of labor after cesarean section. - Gestational age 34 weeks 0 days to 37 weeks 0 days at time of enrollment - Dating of pregnancy by last menstrual period consistent with an ultrasound, ultrasound <21 weeks and 6 days of gestation, or known date of conception in the setting of in vitro fertilization - No known major anomalies (anomalies requiring surgery antenatally or in the neonatal period, anomalies not compatible with life as determined by the physician) - LGA defined as estimated fetal weight (EFW) > 90th percentile by Hadlock formula but <4500 grams Exclusion Criteria: - Pre-gestational diabetes or gestational diabetes on medication (oral or insulin, excluding metformin) - Planned cesarean delivery - Polyhydramnios - Known major fetal anomalies - Multiple gestation or selective reduction of multiple gestation after 14 weeks - Previous stillbirth at term - Indications for delivery at <39 weeks. Common examples include: - Placenta previa - Placenta accreta - Vasa previa - History of classical cesarean section or myomectomy - Human immunodeficiency virus (HIV) - Oligohydramnios (low amniotic fluid, defined as maximum vertical pocket <2.0cm) - High-risk pregnancy as determined by the physician. Common examples include: - Pre-gestational diabetes or gestational diabetes on medication - Chronic hypertension on medication - Maternal cardiac disease - Asthma requiring oral steroids during pregnancy - Chronic renal disease - Antiphospholipid syndrome - Hyperthyroidism - Prior stillbirth - Systemic lupus erythematous - Hemoglobinopathies such as sickle cell disease |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | Harris Health System, Lyndon B Johnson Hospital obstetrics and gynecology clinic |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of children presenting with CNM | Composite neonatal morbidity (CNM) is any of the following: Apgar score <5 at 5 minutes, seizure, fracture of skull, humerus, or clavicle, neonatal brachial plexus palsy, facial nerve palsy, oxygen supplementation >4 hours, CPAP >2 hours, mechanical ventilation, or death before discharge or IUFD. | Up to 6 weeks after delivery | |
Primary | Number of children with birthweight above 4500 grams | Immediately at birth | ||
Secondary | Number of women presenting with CMM | Composite maternal morbidity (CMM) is any of the following: chorioamnionitis, shoulder dystocia, 3rd or 4th degree laceration or episiotomy, transfusion of blood products, endometritis, wound infection or separation, deep venous thrombosis, pulmonary embolism, admission to the intensive care unit, or death. Rates of cesarean section as well as indications in each group will also be evaluated. | Up to 6 weeks after delivery | |
Secondary | Number of children delivered by cesarean section | Immediately at birth | ||
Secondary | Number of children admitted to NICU | NICU is neo-natal intensive care unit | Up to 6 weeks after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00141895 -
A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death
|
Phase 3 | |
Completed |
NCT03039036 -
Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction
|
N/A | |
Completed |
NCT05827731 -
Cervical Double Balloon Combined With Oxytocin
|
N/A | |
Recruiting |
NCT04035382 -
BMI-Associated Labor Induction: A Prospective Trial
|
N/A | |
Withdrawn |
NCT00771511 -
Cervical Capsaicin for Labor Induction and Pain Relief
|
Phase 4 | |
Recruiting |
NCT04075630 -
Observatory on Artificial Labour-induction Methods and Measuring Immediate Postpartum Maternal Satisfaction
|
||
Active, not recruiting |
NCT04573517 -
Early Amniotomy Following Transcervical Foley Balloon in the Induction of Labor
|
N/A | |
Withdrawn |
NCT05257187 -
Foley Catheter Induction
|
N/A | |
Recruiting |
NCT03016442 -
Dinoprostone Vaginal Insert Versus Double Balloon Catheter for Preinduction Cervical Ripening
|
Phase 2 | |
Not yet recruiting |
NCT00984347 -
Breast Stimulation Versus Pitocin for Induction of Labor
|
N/A | |
Completed |
NCT04596397 -
Oral Misoprostol for Outpatient Induction of Labor
|
N/A | |
Completed |
NCT03504670 -
Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00886860 -
The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol
|
Phase 4 | |
Completed |
NCT00504465 -
Combined Agent Randomized Trial of Induction of Labor
|
N/A | |
Completed |
NCT01170819 -
Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening.
|
Phase 4 | |
Completed |
NCT01402050 -
Foley Catheter Versus Cervidil for Induction of Labor at Term
|
N/A | |
Completed |
NCT00529295 -
Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term
|
Phase 3 | |
Completed |
NCT00442663 -
Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction
|
N/A | |
Completed |
NCT00346840 -
Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour
|
Phase 2 | |
Completed |
NCT02639429 -
Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial
|
Phase 4 |